伴EGFR T790M及反式C797S的肺腺癌对第一、三代EGFR TKI联合治疗有效且耐药时C797S等位构型转变
本文报告一例晚期肺腺癌患者,奥希替尼耐药后血浆检出EGFR C797S与T790M呈反式构型,接受厄洛替尼联合奥希替尼治疗后达部分缓解且C797S转为不可测,无进展生存3个月后疾病进展并出现C797S与T790M呈顺式构型。
要点
- 奥希替尼耐药后检出EGFR C797S与T790M反式构型的患者,厄洛替尼联合奥希替尼治疗达部分缓解。
- 联合治疗无进展生存3个月后进展,进展时检出C797S与T790M呈顺式构型。
- C797S由反式向顺式的克隆演变可能是疾病进展的潜在耐药机制。
核心结论
- 本文首次提供临床证据:第一、三代EGFR酪氨酸激酶抑制剂联合方案对同时携带EGFR T790M与反式C797S的患者有效。
- C797S在疾病进展时由反式向顺式的克隆演变,可能是潜在的耐药机制。
研究设计与样本
- 对一例接受靶向治疗的晚期肺腺癌患者,在多个治疗节点采集纵向血浆样本并进行基于捕获的测序。
- 本例患者在奥希替尼耐药时血浆样本显示EGFR C797S与T790M呈反式构型。
主要发现
- 患者在接受厄洛替尼联合奥希替尼治疗后达部分缓解,同时C797S转为不可测。
- 联合治疗的无进展生存为3个月,之后出现疾病进展,进展时检出EGFR C797S与T790M呈顺式构型。
临床怎么用
- 作者报告了第一、三代EGFR酪氨酸激酶抑制剂联合方案靶向EGFR T790M与反式C797S的首次临床疗效证据。
- 作者提出C797S在疾病进展时由反式向顺式的克隆演变可能是潜在的耐药机制。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The efficacy of osimertinib was compromised by the development of resistance mechanisms, such as EGFR C797S. In vitro study proved that cells harboring EGFR C797S in trans with T790M are sensitive to a combination of first- and third-generation EGFR tyrosine kinase inhibitors. However, this has not been reported clinically. METHODS: We performed capture-based sequencing on longitudinal plasma samples obtained at various treatment milestones from a patient with advanced lung adenocarcinoma who was undergoing targeted therapy. RESULTS: At the development of resistance to osimertinib, the patient's plasma sample revealed EGFR C797S located in trans with T790M. He achieved partial response accompanied by undetectable C797S after commencement of a combinatorial treatment consisting of erlotinib and osimertinib. After 3 months of progression-free survival, he experienced progressive disease with emergence of EGFR C797S located in cis to T790M. CONCLUSION: We report the first clinical evidence of efficacy generated by combination therapy consisting of first- and third-generation EGFR tyrosine kinase inhibitors targeting concomitant EGFR T790M and C797S in trans. We also reveal that the clonal progression of C797S from in trans to in cis at disease progression may serve as a potential resistance mechanism.
引用
- Wang Z, Yang JJ, Huang J, et al. Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance. J Thorac Oncol. 2017. PMID: 28662863. doi:10.1016/j.jtho.2017.06.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。